Despite these advancements, the clinical response to immunotherapy varies among individuals, with fewer than 20% of unselected NSCLC patients benefiting from anti-PD-1/PD-L1 therapies (4, 5). Here, PDCD1 is linked to non-small cell lung carcinoma.